Myocardial infarction (MI) leads to cellular death, disturbs electrical function, initiates arrhythmia, and culminates in heart failure, with 50-60% of MI patients dying to sudden cardiac death (SCD). Implantable cardioverter defibrillators (ICDs) are the most efficacious therapy for preventing sudden cardiac death (SCD). Nevertheless, ICDs are known to contribute to unfavorable remodeling and the progression of illness, while not providing protection against arrhythmia. We have created a collagen-PEDOT:PSS hydrogel that can be injected into the heart to prevent ventricular tachycardia (VT) in hearts that have suffered from a heart attack. Additionally, this hydrogel can be used in combination with hiPSC-cardiomyocytes to partially restore the heart's muscle tissue. PEDOT:PSS enhances the process of collagen gel formation, improves the microstructure, and increases conductivity. The hiPSC-cardiomyocytes embedded in collagen-PEDOT:PSS hydrogels demonstrate sarcomeric length similar to that of adult cardiomyocytes, greater contractility, improved calcium handling, and increased conduction velocity. The RNA-sequencing data suggests that there is an increase in the development and improvement of the connections between cells and the extracellular matrix. The administration of collagen-PEDOT:PSS hydrogels into the hearts of mice with infarctions reduces ventricular tachycardia (VT) to the same levels observed in healthy hearts. Collagen-PEDOT:PSS hydrogels provide a diverse substrate for the treatment of damage in electrically sensitive tissues, including the heart.